(Q36307794)

13 August 2017

1 reference

title

Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions (English)

1 reference

13 August 2017

1 reference

1

Adam M Sonabend

1 reference

13 August 2017

Maciej S Lesniak

2

1 reference

13 August 2017

1 November 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

6 Suppl

1 reference

13 August 2017

S25-32

1 reference

Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p.

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Continuous growth of mean tumor diameter in a subset of grade II gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Primary brain tumours in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Successful chemotherapy for recurrent malignant oligodendroglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Correlation between genetic alteration and long‐term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

A tiger behind many doors: multiple genetic pathways to malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Allelic status of chromosome 1 in neoplasms of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Gene expression profiling identifies molecular subtypes of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

Identification of molecular subtypes of glioblastoma by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.S25

21 January 2018

Identifiers

DOI

10.1586/14737175.5.6.S25

1 reference

13 August 2017

1 reference

PubMed ID

16274268